Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma

Immunotherapy is considered one of the most important therapeutic strategies for patients with lung adenocarcinoma after the development of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance. However, useful predictors of immunotherapy for these patients has not been examined well, although the status of the tumor immune microenvironment (TIME), including programmed death‐ligand 1 expression and lymphocyte infiltration, has been generally known to provide predictive markers for the efficacy of immunotherapy. This study aimed to clarify novel predictors of immunotherapy following EGFR‐TKI resistance in lung adenocarcinoma, especially regarding micro RNA (miRNA). We evaluated the correlation between EGFR‐TKI resistance and lymphocyte infiltration, before and after acquiring EGFR‐TKI resistance, in 21 cases of lung adenocarcinoma, and further explored this by in vitro studies, using miRNA PCR arrays. Subsequently, we transfected miRNA‐1 (miR‐1), the most variable miRNA in this array, into three kinds of lung cancer cells, and examined the effects of miR‐1 on EGFR‐TKI sensitivity, cytokine expression and lymphocyte migration. Histopathological examination demonstrated that infiltration levels of CD8‐positive T cells were significantly decreased after development of EGFR‐TKI resistance. In vitro studies revealed that miR‐1 significantly inhibited EGFR‐TKI effect and induction of cytokines, such as C‐C motif chemokine ligand 5 and C‐X‐C motif chemokine ligand 10, causing inhibition of monocyte migration. These results indicate that the upregulated miR‐1 might suppress the TIME, following development of EGFR‐TKI resistance. Therefore, miR‐1 could be a clinically useful marker to predict therapeutic efficacy of immunotherapy in lung adenocarcinoma patients with EGFR‐TKI resistance.

[1]  S. Tomida,et al.  Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[2]  Ke Li,et al.  EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression , 2019, Molecular Cancer.

[3]  T. Yamanaka,et al.  The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.

[4]  V. De Rosa,et al.  The Multifaceted Interface Between Cytokines and microRNAs: An Ancient Mechanism to Regulate the Good and the Bad of Inflammation , 2018, Front. Immunol..

[5]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[8]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[9]  T. Mitsudomi,et al.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  S. Yuspa,et al.  Cell autonomous or systemic EGFR blockade alters the immune‐environment in squamous cell carcinomas , 2016, International journal of cancer.

[12]  C. Weaver,et al.  IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21–producing B helper CD8+ T cells , 2016, The Journal of experimental medicine.

[13]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[14]  S. Eliason,et al.  MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation , 2016, PloS one.

[15]  K. O'Byrne,et al.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.

[16]  J. Shan,et al.  Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson’s Disease , 2016, PloS one.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  A. Jemal,et al.  Long-Term Realism and Cost-Effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide , 2015, Journal of the National Cancer Institute.

[19]  Thomas J. Smith,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jia-Nan Cheng,et al.  EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. , 2015, Biochemical and biophysical research communications.

[21]  Bin Zhang,et al.  Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma , 2015, Oncotarget.

[22]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[23]  K. Ansel,et al.  MicroRNA regulation of lymphocyte tolerance and autoimmunity. , 2015, The Journal of clinical investigation.

[24]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[25]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[26]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[27]  H. Sasano,et al.  An activation of LC3A‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma , 2014, The Journal of pathology.

[28]  I. Ismail,et al.  Nanoscale Diblock Copolymer Micelles: Characterizations and Estimation of the Effective Diffusion Coefficients of Biomolecules Release through Cylindrical Diffusion Model , 2014, PloS one.

[29]  C. Creighton,et al.  miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer , 2014, PloS one.

[30]  W. Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[31]  S. Greenberg,et al.  Inhibition of Myogenic MicroRNAs 1, 133, and 206 by Inflammatory Cytokines Links Inflammation and Muscle Degeneration in Adult Inflammatory Myopathies , 2014, Arthritis & rheumatology.

[32]  Koichi Goto,et al.  RET fusion gene: Translation to personalized lung cancer therapy , 2013, Cancer science.

[33]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Xiaonan H. Wang MicroRNA in myogenesis and muscle atrophy , 2013, Current opinion in clinical nutrition and metabolic care.

[35]  P. Jänne,et al.  New targetable oncogenes in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Pengyuan Yang,et al.  MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. , 2012, Life sciences.

[37]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[38]  D. Cooper,et al.  Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression , 2012, The Journal of Immunology.

[39]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[40]  W. Pao,et al.  Chipping away at the lung cancer genome , 2012, Nature Medicine.

[41]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[42]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[43]  A. Gemma,et al.  F1000 highlights , 2010 .

[44]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[45]  F. Hirsch,et al.  EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Y. Hayashizaki,et al.  Cancer research with non‐coding RNA , 2006, Cancer science.

[47]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[48]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[49]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[50]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[51]  David E. Misek,et al.  RANTES expression is a predictor of survival in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  T. Tuschl,et al.  Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.

[53]  D. Taub,et al.  T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. , 1996, The Journal of clinical investigation.

[54]  J. Roa,et al.  miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. , 2014, International journal of clinical and experimental pathology.